Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 124

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 124
---
 derived from WO 2005/061018) has expiration dates in December 2025, additional patent families of the Company,
have later expiration dates, and cover improvements as detailed herein. In particular, while the basic patent estate is directed to the
specific ingredients of GelrinC, the latest family of patents and patent applications (derived from WO 2017/103924) is instead directed
to a final product; however, the latest patent applications derived from WO 2017/103924 have only been granted in China and the other
patent applications may not mature into actual patents. The final product uses a ready–for–use formulation technology and
the process of manufacture of the final product avoids the use of acetone, which may become forbidden under advanced guidelines for products
introduced into the body. Therefore, we believe that upon approval in different territories, additional patents could provide the Company
with sufficient protection from completion even after the expiration dates of the basic patent estate.

GelrinC

GelrinC utilizes a conjugate
of denatured fibrinogen and polyethylene glycol and the intended clinical use of this product is to treat focal cartilage injuries. These
specific conjugate molecules are disclosed and claimed in the earliest patent family of the Company derived from WO 2005/061018, which
are nominally due to expire in December 2025. In various countries, patent term extension or supplementary protection certificates are
available upon receipt of marketing approval to prolong the period of exclusivity of a new medical product. The earliest patent family
of the Company derived from WO 2005/061018 includes patents Nos. US 7,842,667, US 8,007,774, US 8,858,925, US 9,120,872, US 9,474,830,
US 9,700,600 and EP 1870115, which are detailed in the table below.

While the first family of
patents form the “basic patent estate” covering the current products of the Company, diligent efforts have been made by the
Company to cover improvements and alternatives. Our “basic patent estate” has expiration date in December 2025. Although
the patents included in this “basic patent estate” are close to expiring, such patents only cover certain components in the
Company’s products. Our additional subsequently granted patents provide supplementary protection, as well as the latest pending
patent applications which cover subsequent improvements in